Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    Steven Kayser, PharmD

    TitleProfessor
    SchoolUCSF School of Pharmacy
    DepartmentClinical Pharmacy
    Address521 Parnassus Ave, Clinic Sci
    San Francisco CA 94143
    Phone415-476-4540

       Bibliographic 
       Publications
      Publications by year:
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      1. Alldredge BK, Kayser SR. Bending the curve toward increased use of generic drugs: comment on "when choosing statin therapy". JAMA Intern Med. 2013 Feb 11; 173(3):233-4.
        View in: PubMed
      2. Johnson SG, Kayser SR, Attridge RL, Duvall L, Kiser TH, Moote R, Reed BN, Rodgers JE, Erstad B. Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update. Pharmacotherapy. 2012 Jun; 32(6):e134-69.
        View in: PubMed
      3. Shin J, Kayser SR. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy. 2011 Sep; 31(9):863-70.
        View in: PubMed
      4. Cheng CM, McCurdy MR, Wong HA, Kayser SR. Pros and cons of dabigatran. Am J Health Syst Pharm. 2011 Aug 15; 68(16):1495.
        View in: PubMed
      5. Meeker E, Dennehy CE, Weber EJ, Kayser SR. Emergency department management of patients on warfarin therapy. Ann Emerg Med. 2011 Aug; 58(2):192-9.
        View in: PubMed
      6. Kadafour M, Haugh R, Posin M, Kayser SR, Shin J. Survey on warfarin pharmacogenetic testing among anticoagulation providers. Pharmacogenomics. 2009 Nov; 10(11):1853-60.
        View in: PubMed
      7. Shin J, Kayser SR, Langaee TY. Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm. 2009 Apr 1; 66(7):625-37.
        View in: PubMed
      8. Cheng CM, Meyer-Massetti C, Kayser SR. A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther. 2009 Jan; 31(1):32-41.
        View in: PubMed
      9. Kayser SR. The use of nesiritide in the management of acute decompensated heart failure. 2002. Prog Cardiovasc Nurs. 2007; 22(4):89-95.
        View in: PubMed
      10. Kayser SR. Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease. Prog Cardiovasc Nurs. 2007; 22(2):104-7.
        View in: PubMed
      11. Kayser SR. Dronedarone: in quest of the ideal antiarrhythmic drug. Prog Cardiovasc Nurs. 2007; 22(4):221-4.
        View in: PubMed
      12. Boettger R, Lee J, Rifkin C, Kayser SR. Heart transplantation and altered drug response, Part II: pharmacologic management of post-transplantation complications. Prog Cardiovasc Nurs. 2006; 21(4):219-22.
        View in: PubMed
      13. Boettger R, Lee J, Rifkin C, Kayser S. Heart transplantation and altered drug response, part I: heart transplantation and innervation. Prog Cardiovasc Nurs. 2006; 21(2):100-3.
        View in: PubMed
      14. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005 Jun; 39(6):1008-12.
        View in: PubMed
      15. Kayser SR. Combination drug therapy in the management of pulmonary arterial hypertension. Prog Cardiovasc Nurs. 2005; 20(4):177-82.
        View in: PubMed
      16. Kayser SR. Practical challenges in the management of oral anticoagulation. Prog Cardiovasc Nurs. 2005; 20(2):80-5.
        View in: PubMed
      17. Voirol P, Kayser SR, Chang CY, Chang QL, Youmans SL. Impact of pharmacists' interventions on the pediatric discharge medication process. Ann Pharmacother. 2004 Oct; 38(10):1597-602.
        View in: PubMed
      18. Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM. Famotidine and long QT syndrome. Am J Cardiol. 2004 May 15; 93(10):1325-7.
        View in: PubMed
      19. Kayser SR. Dilemmas in drug therapy. Prog Cardiovasc Nurs. 2003; 18(2):108-11.
        View in: PubMed
      20. Ho R, Kayser SR. Thrombocytopenia associated with antithrombotic therapy in acute coronary syndrome. Prog Cardiovasc Nurs. 2003; 18(4):198-200.
        View in: PubMed
      21. McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother. 2002 Jun; 36(6):1042-57.
        View in: PubMed
      22. Kayser SR. The use of nesiritide in the management of acute decompensated heart failure. Prog Cardiovasc Nurs. 2002; 17(2):89-95.
        View in: PubMed
      23. Glatter K, Yang Y, Chatterjee K, Modin G, Cheng J, Kayser S, Scheinman MM. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation. 2001 Jan 16; 103(2):253-7.
        View in: PubMed
      24. Kato Y, Fujii T, Mizoguchi N, Takata N, Ueda K, Feldman MD, Kayser SR. Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul; 20(7):851-4.
        View in: PubMed
      25. Kayser SR. Spironolactone in the management of congestive heart failure. Prog Cardiovasc Nurs. 2000; 15(4):145-8.
        View in: PubMed
      26. Kayser SR. Low-molecular-weight heparins in the management of cardiovascular conditions. Prog Cardiovasc Nurs. 1998; 13(1):34-40.
        View in: PubMed
      27. Kayser SR. Use of epoprostenol (Flolan) in the management of primary pulmonary hypertension. Prog Cardiovasc Nurs. 1998; 13(3):39-41, 45.
        View in: PubMed
      28. Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med. 1997 Jun 15; 126(12):959-62.
        View in: PubMed
      29. Banerji S, Kayser SR. Antiarrhythmic drug therapy--Part IV: Ventricular arrhythmias. Prog Cardiovasc Nurs. 1997; 12(3):32-6.
        View in: PubMed
      30. Kayser SR. Clinical trials update. Prog Cardiovasc Nurs. 1997; 12(2):30-3, 44.
        View in: PubMed
      31. Kayser SR. Ibutilide--a new drug for the rapid termination of atrial fibrillation and atrial flutter. Prog Cardiovasc Nurs. 1997; 12(1):39-43.
        View in: PubMed
      32. Kayser SR. Dilemmas in drug therapy. Prog Cardiovasc Nurs. 1997; 12(4):29-31, 33.
        View in: PubMed
      33. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, Lotan R, Hong WK. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 1996 Dec 15; 56(24):5600-4.
        View in: PubMed
      34. Kayser SR. Antiarrhythmic drug therapy--Part II: Specific drugs. Prog Cardiovasc Nurs. 1996; 11(3):33-8.
        View in: PubMed
      35. Kayser SR. Antiarrhythmic drug therapy--part III: atrial fibrillation. Prog Cardiovasc Nurs. 1996; 11(4):35-43,45.
        View in: PubMed
      36. Kayser SR. Antiarrhythmic drug therapy--Part I: General principles of drug selection. Prog Cardiovasc Nurs. 1996; 11(2):33-7.
        View in: PubMed
      37. Kayser SR. Management of venous thromboembolic (VTE) disease--Part II: Treatment. Prog Cardiovasc Nurs. 1996; 11(1):36-40, 46.
        View in: PubMed
      38. Kayser SR. Management of venous thromboembolic (VTE) disease--Part I: Prevention. Prog Cardiovasc Nurs. 1995; 10(4):31-6.
        View in: PubMed
      39. Kayser SR. Calcium channel blockers--is vasoselectivity relevant? Prog Cardiovasc Nurs. 1995; 10(1):35-9.
        View in: PubMed
      40. Trujillo T, Kayser SR. Alcohol and cardiovascular disease. Prog Cardiovasc Nurs. 1995; 10(2):36-9, 46.
        View in: PubMed
      41. Kayser SR. Pharmacologic management of cardiac arrest: an update perspective. Prog Cardiovasc Nurs. 1995; 10(3):35-41.
        View in: PubMed
      42. Kayser SR. New drugs 1994: trapidil, torsemide. Prog Cardiovasc Nurs. 1994; 9(3):38-40.
        View in: PubMed
      43. Quan DJ, Kayser SR. Ketorolac induced acute renal failure following a single dose. J Toxicol Clin Toxicol. 1994; 32(3):305-9.
        View in: PubMed
      44. Kayser SR. Management of chronic congestive heart failure. Part II--Selection of treatment. Prog Cardiovasc Nurs. 1994; 9(2):30-7.
        View in: PubMed
      45. Kayser SR. Management of chronic congestive heart failure: Part I--General introduction to treatment. Prog Cardiovasc Nurs. 1994; 9(1):39-42.
        View in: PubMed
      46. Kayser SR, Trujillo T. The role of magnesium in cardiovascular disease. Prog Cardiovasc Nurs. 1994; 9(4):37-40.
        View in: PubMed
      47. Kayser SR. Drug interaction with coumarin anticoagulants. Prog Cardiovasc Nurs. 1993; 8(1):40-5.
        View in: PubMed
      48. Callaham M, Barton CW, Kayser S. Potential complications of high-dose epinephrine therapy in patients resuscitated from cardiac arrest. JAMA. 1991 Mar 6; 265(9):1117-22.
        View in: PubMed
      49. De Marco T, Daly PA, Liu M, Kayser S, Parmley WW, Chatterjee K. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. J Am Coll Cardiol. 1987 May; 9(5):1131-8.
        View in: PubMed
      50. Davis LJ, Kayser SR, Hubsher J, Williams RL. Effect of oxaprozin on the steady-state anticoagulant activity of warfarin. Clin Pharm. 1984 May-Jun; 3(3):295-7.
        View in: PubMed
      51. Watanabe AS, McCart G, Shimomura S, Kayser S. Systematic approach to drug information requests. Am J Hosp Pharm. 1975 Dec; 32(12):1282-5.
        View in: PubMed
      Steven's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      See all (225) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (10) people
      _
      Related Authors
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Back to TOP